Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

NCT04625270 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT04625270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04625270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Lead sponsor
Verastem, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 21, 2020
Completion date
December 31, 2026
Enrollment
225 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

low grade ovarian serous adenocarcinoma, ovarian cancer